InvestorsHub Logo
Followers 2
Posts 1360
Boards Moderated 0
Alias Born 01/05/2018

Re: None

Thursday, 04/19/2018 4:51:34 AM

Thursday, April 19, 2018 4:51:34 AM

Post# of 21521
I just realized that Biogen is in deep trouble if Bryostatin makes it to the market.

https://www.biogen.com/en_us/research-pipeline/biogen-pipeline.html

More than half their pipeline consists of drugs for neurodegenerative disorders, and all their AD drugs seem to be going for the amyloid approach.

Imagine how investors will react when they see a smaller competitor put a drug on the market that does the job of more than half their entire pipeline.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News